What changed
Deals & ownershipDanaher Corporation disclosed a series of insider transactions from November 2026, including stock sales, option exercises, and equity grants. Activities included a notice of a proposed sale of 23,010 shares by a former officer and routine transactions by top management to withhold shares for tax payments.

What changedDanaher raised third-quarter 2026 revenue 8.5% to $6.6 billion and raised its full-year profit outlook. Adjusted earnings per share rose 11.5% to $2.11.

What changedJulie Sawyer Montgomery стала президентом і генеральним директором Данахера 1 жовтня 2026 р.

Company history
October 2026
DANAHER CORP /DE/: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-06-27 to 2026-09-25: 6,554,000,000 USD (6.6 billion; 6,554 million); same period a year earlier (2025-06-28 to 2025-09-26): 6,053,000,000 USD (6.1 billion; 6,053 million); change +8.3% Source
- 2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-25: 18,770,000,000 USD (18.8 billion; 18,770 million); same period a year earlier (2025-01-01 to 2025-09-26): 17,730,000,000 USD (17.7 billion; 17,730 million); change +5.9% Source
- 2026-10-21: Gross profit (us-gaap:GrossProfit), quarter 2026-06-27 to 2026-09-25: 3,837,000,000 USD (3.8 billion; 3,837 million); same period a year earlier (2025-06-28 to 2025-09-26): 3,523,000,000 USD (3.5 billion; 3,523 million); change +8.9% Source
- 2026-10-21: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-25: 11,039,000,000 USD (11 billion; 11,039 million); same period a year earlier (2025-01-01 to 2025-09-26): 10,557,000,000 USD (10.6 billion; 10,557 million); change +4.6% Source
- 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-06-27 to 2026-09-25: 1,245,000,000 USD (1.2 billion; 1,245 million); same period a year earlier (2025-06-28 to 2025-09-26): 1,154,000,000 USD (1.2 billion; 1,154 million); change +7.9% Source
- 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-25: 3,716,000,000 USD (3.7 billion; 3,716 million); same period a year earlier (2025-01-01 to 2025-09-26): 3,188,000,000 USD (3.2 billion; 3,188 million); change +16.6% Source
- 2026-10-21: Net income (us-gaap:NetIncomeLoss), quarter 2026-06-27 to 2026-09-25: 1,235,000,000 USD (1.2 billion; 1,235 million); same period a year earlier (2025-06-28 to 2025-09-26): 908,000,000 USD (908 million); change +36% Source
- 2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-25: 3,134,000,000 USD (3.1 billion; 3,134 million); same period a year earlier (2025-01-01 to 2025-09-26): 2,417,000,000 USD (2.4 billion; 2,417 million); change +29.7% Source
- 2026-10-21: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-06-27 to 2026-09-25: 433,000,000 USD (433 million); same period a year earlier (2025-06-28 to 2025-09-26): 378,000,000 USD (378 million); change +14.6% Source
- 2026-10-21: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-25: 1,232,000,000 USD (1.2 billion; 1,232 million); same period a year earlier (2025-01-01 to 2025-09-26): 1,160,000,000 USD (1.2 billion; 1,160 million); change +6.2% Source
- 2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-25: 4,742,000,000 USD (4.7 billion; 4,742 million); same period a year earlier (2025-01-01 to 2025-09-26): 4,299,000,000 USD (4.3 billion; 4,299 million); change +10.3% Source
- 2026-10-21: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-25: 761,000,000 USD (761 million); same period a year earlier (2025-01-01 to 2025-09-26): 785,000,000 USD (785 million); change -3.1% Source
July 2026
Danaher Corp reported second quarter 2026 financial results and continues the integration of Masimo.
- For the three-month period ended June 26, 2026, the Company reported that overall revenues and core sales increased 5.5% and 3.0%, respectively, compared to 2025, while price decreases of 0.5% negatively impacted sales growth. Source
- The Company is engaged in the integration of Masimo, an acquisition for which the Company incurred debt to finance a portion of the purchase price. Source
- For the six-month period ended June 26, 2026, the Company’s overall revenues and core sales increased 4.5% and 2.0%, respectively, compared to the comparable period of 2025. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Changes in risk factors
The 10-Q filed October 21, 2026 compared with the 10-Q filed July 21, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (18)
- efficiency and quality and effectively address the demands of an increasingly regulated global environment and the evolving trade environment. The Company is making significant investments, organically and through acquisitions and investments, to address the rapid pace of technological change and increasing demand for automation in its served markets and to position its manufacturing, research and development and customer-facing resources to be responsive to the Company’s customers throughout the world and improve the efficiency of the Company’s operations.
- In addition to the Masimo Acquisition, during the three and nine-month periods ended September 25, 2026, the Company acquired one business for total upfront consideration of $37 million in cash and $79 million of deferred consideration. The business acquired complements existing units of the Company’s Life Sciences segment. The Company preliminarily recorded an aggregate of $26 million of goodwill related to this acquisition and $144 million of identifiable intangible assets, of which a majority related to developed technology intangible assets. The annual sales of this business in its last…
- •the impact of tariff refunds received by the Company and returned (or expected to be returned) to customers.
Dropped (6)
- the Company and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult. The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
- | June 26, 2026 | | June 27, 2025 | | June 26, 2026 | | June 27, 2025
- ($ in millions) | June 26, 2026 | | June 27, 2025 | | June 26, 2026 | | June 27, 2025
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| October 13, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| September 30, 2026 | Removal of a security from listing (Form 25) | 25-NSE |
| August 3, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 10, 2026 | Couchara Georgeann | Planned sale | 23,010 | — | $5,411,800 | SEC |
| November 9, 2026 | Blair Rainer | Planned sale 10b5-1 plan | 71,963 | — | $16,854,420 | SEC |
| November 9, 2026 | Matthew McGrew | Sale notice filed | 17,385 | $235.69 | $4,097,452 | SEC |
| November 9, 2026 | Gregory M Milosevich | Sale notice filed | 2,100 | $230.62 | $484,302 | SEC |
| October 28, 2026 | Matthew McGrew | Sale | 29,754 | $235.74 | $7,014,244 | SEC |
| October 28, 2026 | Christopher Bouda | Sale | 7,598 | $234.56 | $1,782,157 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 53,976,143 | $11,958,414,464 | -2.0% | Q3 2026 |
| Fidelity (FMR) | 38,707,539 | $8,575,655,214 | +31.0% | Q3 2026 |
| State Street | 28,547,173 | $6,335,876,761 | +0.3% | Q3 2026 |
| Capital Research Global Investors | 15,995,884 | $3,544,121,287 | +47.9% | Q3 2026 |
| Geode Capital Management | 14,384,878 | $3,171,976,288 | +0.7% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 9,537,906 | $1,816,780,335 | — | Q2 2026 |
| Wellington Management | 6,588,621 | $1,459,708,983 | -59.6% | Q3 2026 |
| Tiger Global Management | 1,268,800 | $281,102,640 | +178.2% | Q3 2026 |
| Millennium Management | 1,246,331 | $276,124,633 | -41.8% | Q3 2026 |
| Citadel Advisors | 725,217 | $160,671,827 | -23.2% | Q3 2026 |
| Renaissance Technologies | 760,636 | $144,885,945 | +12.1% | Q2 2026 |
| Third Point (Dan Loeb) | 540,000 | $102,859,200 | +2.9% | Q2 2026 |
| D. E. Shaw & Co. | 461,715 | $102,292,958 | +12.1% | Q3 2026 |
| Bridgewater Associates | 396,238 | $87,786,529 | +1,442.7% | Q3 2026 |
| Two Sigma Investments | 82,018 | $18,171,088 | -81.9% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.